Legionellosis News and Research

RSS

Microbiome composition influences severity of Legionnaires' disease

Pneumonia is an infection of the lung alveoli caused by bacteria, viruses or fungi. It is one of the leading causes of morbidity and mortality worldwide, representing a clinical and economic burden and a global public health problem.

13 Sep 2023

How can Legionella pneumophila transmit through the hot water plumbing of residences and office buildings?

Researchers investigate the transmission of the causative agent of legionellosis, Legionella pneumophila, through hot water plumbing systems in commercial and residential buildings.

8 Sep 2022

Record number of Legionnaires’ cases in 2018 risk lives, cause cleanup headaches

Cases of Legionnaires' disease reached a record high in 2018 — a more than eight-fold increase since the numbers began to climb nearly two decades ago.

5 Nov 2019

New study examines presence of microbes in tap water from residences, office buildings

Water is a source of concern for disseminating the bacteria Legionella pneumophila and Mycobacterium avium, which cause lung disease (legionellosis and pulmonary nontuberculous mycobacterium disease, respectively).

21 Mar 2019

Waterborne disease outbreaks can be traced to plumbing systems in buildings

Traditional water treatment efforts have focused on water leaving the treatment plant, but a large number of recent waterborne disease outbreaks in the U.S. can be traced to plumbing systems in buildings.

9 Nov 2017

Study sheds light on virulence strategy of intracellular bacteria that cause legionellosis

Intracellular pathogens adopt various strategies to circumvent the defences of the host cell and to proliferate intracellularly. One specific strategy is to target host organelles like the mitochondria. Mitochondria are well-defined cytoplasmic organelles, which take part in a variety of cellular metabolic functions.

7 Sep 2017

Researchers report first case of acute myelitis due to Zika virus infection

A first case of acute myelitis following infection with Zika virus has been reported for the first time by a research team from Inserm Unit 1127 Brain and Spinal Cord Institute (Inserm/CNRS/Sorbonne University) and neurologists at Pointe-à-Pitre University Hospital and the University of the Antilles.

9 Mar 2016

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

FDA clears Meridian Bioscience's TRU Legionella test

Meridian Bioscience, Inc. today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella, a new rapid assay for detection of legionellosis.

28 Feb 2012

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011

Legionnaire’s bug in Playboy mansion hot tub

Health officials have been able to trace the cause of the outbreak of Legionnaires’ disease after a two-month investigation. They found the bug in the hot tub of the Playboy mansion.

17 Apr 2011

Legionnaires' disease kills a 66 year old

There has been a death with Legionnaire’s disease in Doncaster. This disease is caused by bacteria that infects people when they breathe in infested water droplets, such as spray drifts from cooling towers.

3 Jun 2010

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010